Personalized mRNA Cancer Vaccine Significantly Reduces Melanoma Recurrence

A landmark Phase 3 clinical trial (INTerpath-001) has shown that adding an individualized mRNA-based neoantigen therapy, intismeran, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42% compared to pembrolizumab alone. This represents a significant advance in cancer treatment, marking the first time an mRNA cancer treatment has been proven effective in a large international clinical trial. The results were presented at the European Society for Medical Oncology (ESMO) Congress 2026.